Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient

摘要

Vision-threatening JIA (juvenile idiopathic arthritis)-associated uveitis unresponsive to corticosteroids, immunosuppressive drugs, and anti-TNF agents is likely to require further biologic response modifier therapy to target alternate cytokines involved in the inflammatory pathways. We present one case of anterior nongranulomatous uveitis in a pediatric patient refractory to anti-TNF therapy who responded favorably to tocilizumab (TCZ), a monoclonal antibody against the interleukin-6 receptor (IL-6).